Already a top oncology player, Bristol Myers will gain via the deal an approved lung cancer drug and three other experimental medicines now in clinical testing.Bristol Myers Squibb has agreed to acquire cancer drug developer Mirati Therapeutics for $4.8 billion, and possibly more, in a deal that would strengthen its position as a dominant player […]
